ACTU

Actuate Therapeutics Inc

Insider Trades

ActorHolding ValueLast TransactionAmountTransaction PriceCurrent Price
Fletcher Aaron G.L.Director, 10% Owner
--15k shares
Grant / ExerciseMay 21, 2026
Disclosure amount unavailable15k shares
--
$2.08
Huber Martin H. Jr.Director
--15k shares
Grant / ExerciseMay 21, 2026
Disclosure amount unavailable15k shares
--
$2.08
Keyes Jason ADirector
--15k shares
Grant / ExerciseMay 21, 2026
Disclosure amount unavailable15k shares
--
$2.08
Ronneberg Amy LDirector
--15k shares
Grant / ExerciseMay 21, 2026
Disclosure amount unavailable15k shares
--
$2.08
Sawhney RogerDirector
--15k shares
Grant / ExerciseMay 21, 2026
Disclosure amount unavailable15k shares
--
$2.08
Fletcher Aaron G.L.Director, 10 Percent Owner:
--15k shares
Grant / ExerciseMay 21, 2026
$36.3K15k shares
$2.42
$2.08

News

globenewswire.comActuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastomaglobenewswire.comJun 9globenewswire.comActuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancerglobenewswire.comJun 1globenewswire.comActuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Programglobenewswire.comMay 11invezz.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?invezz.comMay 9globenewswire.comActuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directorsglobenewswire.comMay 6